Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma

BACKGROUND: The anti-VEGF antibody, bevacizumab, is standard treatment for patients with recurrent glioblastoma. In this setting, traditional anatomic MRI methods such as post-contrast T1-weighted and T2-weighted imaging are proving unreliable for monitoring response. Here we evaluate the prognostic...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Schmainda, Kathleen M., Prah, Melissa, Connelly, Jennifer, Rand, Scott D., Hoffman, Raymond G., Mueller, Wade, Malkin, Mark G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2014
Gaiak:
Neuroimaging
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4022214/
https://ncbi.nlm.nih.gov/pubmed/24431219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not216
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak